IL4: Interleukin-4
Cytokine secreted primarily by mast cells, T-cells, eosinophils, and basophils that plays a role in regulating antibody production, hematopoiesis and inflammation, and the development of effector T-cell responses.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on IL4, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 2
| Pascolizumab | Phase 2 | Facet Biotech | Antibody | InhibitorInterleukin-4 inhibitor | 0 |
| Romilkimab | Phase 2 | Sanofi | Antibody | InhibitorInterleukin-4 inhibitor | 0 |
- Asthma0.47
- Atopic eczema0.40
- Ischemic stroke0.38
- Allergic rhinitis0.35
- Respiratory system disorder0.35
- Psoriasis0.34
- Allergic disease0.33
- Childhood onset asthma0.29
- Lower respiratory tract disorder0.28
- Deep vein thrombosis0.28
- Chronic bronchitis0.28
- Abnormal thrombosis0.27
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712894, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P05112, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets